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The monitoring of the cardiac output (CO) and other hemodynamic parameters, traditionally performed with the
thermodilution method via a pulmonary artery catheter (PAC), is now increasingly done with the aid of less invasive
and much easier to use devices. When used within the context of a hemodynamic optimization protocol, they can
positively influence the outcome in both surgical and non-surgical patient populations. While these monitoring
tools have simplified the hemodynamic calculations, they are subject to limitations and can lead to erroneous
results if not used properly. In this article we will review the commercially available minimally invasive CO
monitoring devices, explore their technical characteristics and describe the limitations that should be taken into
consideration when clinical decisions are made.
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The need for the precise quantification of cardiac output
(CO) in high-risk surgical patients, both in the operative
room and the intensive care unit, is vital in modern
medical practice. While up to 20 years ago CO had to be
estimated from the PAC, nowadays new, less invasive
techniques are available. When used together with peri-
operative protocols aiming at improving CO and oxygen
delivery (DO2), their use is referred to as hemodynamic
optimization or goal-directed therapy (GDT) [1].
Much has changed since the introduction of the pulmon-
ary artery catheter (PAC) by Swan and Ganz in 1970 for
the measurement of CO using the thermodilution method.
Although in the context of moderate and high-risk surgery
the beneficial effect of the PAC combined with goal di-
rected therapy (GDT) has been established in a recent
meta-analysis [2], the invasive nature of the insertion of the
catheter and a considerable number of complications that* Correspondence: hamos1977@yahoo.gr
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reproduction in any medium, provided the orfollow its use (infection, arrhythmias, thrombosis, and pul-
monary artery rupture) have led to a decline in its popular-
ity, and prompted the scientific community to search for
alternative methods that could substitute the PAC.
The term ‘minimally invasive cardiac monitoring’ en-
compasses all the methods and devices that calculate the
cardiac output without the need of inserting a PAC, ran-
ging from methods almost non-invasive to marginally
less invasive than the PAC. These include the pulse pres-
sure analysis, the transpulmonary thermodilution, the in-
dicator dilution, the esophageal Doppler, the thoracic
electrical bioimpedance, the carbon dioxide rebreathing,
and the echocardiography. Since each one of these de-
vices utilizes a different method of estimating the cardiac
output, the clinician should be aware of their distinct
features, their limitations but also the sources of poten-
tial error that stem for their use.Review
Pulse pressure analysis
The pulse pressure analysis uses the arterial waveform,
obtained either from an arterial catheter or a fingerl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the systemic vascular resistance (SVR).
Its principles first described by Erlanger and Hooker
in 1904 [3], pulse pressure analysis is based on the hy-
pothesis that the SV is proportional to the arterial pulse
pressure. However, a major drawback was the fact that
the compliance of the aortic wall is non-linear rather
than linear, being high at low distending pressures but
decreasing more rapidly at higher pressures, preventing
this way the overstretching of the vessel wall.
This and the fact that the compliance is also age-
related, prevented any straightforward correlation of the
pressure to the volume [4]. Only in 1983 and after the
development of an algorithm by Wesseling et al. [5] to
compensate for this non-linearity, did it become possible
to calculate the SV by integrating the area under the
curve of the systolic phase of the arterial waveform, and
calculating the CO by simply multiplying the SV with
the heart rate (HR) Figure 1.
One should always keep in mind that the pulse pres-
sure method relies heavily on an optimal arterial pres-
sure tracing, making an under- or over-damped arterial
waveform a potential source of errors in calculation.
Moreover, the pulse pressure systems necessitate an ar-
terial wave that is purely reflective of the forward SV. As
a consequence, situations in which the arterial wave is
distorted either by artifact or a physiologic phenomenon
(intra-aortic balloon counterpulsation, aortic regurgita-
tion) will lead to inaccuracies [6]. Finally, the discrep-
ancy in the compliance of the aorta compared to more
peripheral parts of the arterial tree distorts the pattern
of the arterial waveform and requires a careful interpret-
ation of the measured values.
A variety of commercial systems that make use of the
pulse pressure analysis method are available and they are
divided in two groups, depending on the way that they areFigure 1 The area under the curve (AUC) of the systolic phase
is indicative of the SV. The SV is the shaded area under the systolic
portion of the arterial pulse waveform. It is calculated as=[area under
systolic phase+ aortic compliance] x shape of pressure curve.calibrated. Monitors that are ‘autocalibrated’ consist of the
FloTrac/Vigileo, the Pulsioflex, the LidCO rapid, and the
recently introduced Nexfin and esCCO monitors. On the
other hand, there are devices that are externally calibrated:
the PiCCOplus and the recently developed EV1000 use
the transpulmonary thermodilution method, while the
LidCO plus utilizes the lithium dilution technique for the
same purpose. Moreover, apart from being useful tools in
CO calculations, these monitors can also help predict the
fluid responsiveness, as will be discussed later in this re-
view article.
Uncalibrated devices
Connected to a standard indwelling arterial catheter, the
FloTrac sensor (Edwards Lifesciences, Irvine, CA, USA)
uses an upgraded algorithm that derives the SV from the
pulse pressure (PP) of the arterial waveform, after
correcting for the compliance and the resistance of the
arterial system.
A similar pulse pressure analysis method is used by
the ProAQT sensor which is incorporated in the
Pulsioflex monitor (Pulsion Medical Systems, Munich,
Germany). Utilizing an existing peripheral arterial cath-
eter and analyzing the arterial waveform 250 times per
second, a start value for CO trend monitoring is deter-
mined after the patient’s characteristics are inserted to
the system. To increase accuracy, a CO value measured
by another method (for example by echocardiography)
can be entered and thus the system can be externally
calibrated.
As for the LidCO rapid system (LidCO Ltd, Cambridge,
UK), it is based on the same algorithm as the LidCO plus
monitor (which will be described later), but instead of
thermodilution it relies on nomograms for the calculation
of the CO.
One of the latest additions to the field of minimally in-
vasive CO monitoring is the Nexfin monitor (BMEYE,
Amsterdam, The Netherlands). Rather than a minimally
invasive monitor, it is a completely non-invasive method
of determining the patient’s hemodynamic parameters,
as the need for an invasive arterial catheter is obviated.
The monitor is connected to the patient by wrapping an
inflatable cuff around the middle phalanx of the finger.
The pulsating finger artery is ‘clamped’ to a constant
volume by applying a varying counter pressure equiva-
lent to the arterial pressure resulting in a pressure wave-
form. The finger arterial pressure is then reconstructed
into brachial arterial pressure waveform using a transfer
function and a level correction based on a vast clinical
database. The resulting brachial pressure waveform
serves as the basis for determining continuous CO.
Real-time continuous CO and other hemodynamic pa-
rameters are derived by a novel pulse contour method
(Nexfin CO-Trek®), which is based on the systolic
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model individualized for each patient. Moreover, the pres-
ence of a co-oximeter enables the non-invasive calculation
of hemoglobin, from which the oxygen delivery index
(DO2I) is derived.
For completion purposes, we should also mention the
latest entry in the pulse pressure analysis field, under the
name of esCCO (Nihon Kohden, Tokyo, Japan). Also be-
ing a non-invasive monitor, it uses a new technology
that derives the CO using the Pulse Wave Transit Time
(PWTT), which is obtained by the pulse oximetry and
the ECG signals of each cardiac cycle. The rationale be-
hind this is that animal studies have shown a strong
correlation between the SV and the PWTT. The only
up-to-date validation study has demonstrated a clinic-
ally unacceptable performance of the device when com-
pared to the CO values obtained with transthoracic
echocardiography [7].
The accuracy of the pulse pressure analysis method in
estimating CO has been extensively investigated against
CO calculations by the thermodilution method using the
PAC. This holds true particularly for the FloTrac/Vigileo
monitoring. In one of the most recent meta-analyses,
Mayer et al. [8] showed improved correlation between
the Flotrac/Vigileo and the thermodilution method when
the new generation software was used, as opposed to the
initially poor correlation with previous generation soft-
wares. Also, the SVV calculated with this method
showed good performance in predicting fluid respon-
siveness in septic shock patients [9]. On the other hand,
it appears that the CO calculated by the FloTrac/Vigileo
has a less accurate correlation with the one derived by
the PAC when changes are induced by norepinephrine
administration [10], and also tends to be overestimated
compared to a continuous cardiac output calculation
with a PAC when used in off-pump coronary artery by-
pass surgery (CABG) [11]. A discrepancy in measure-
ments also appears when the FloTrac/Vigileo is used to
calculate hemodynamic parameters in open aortic ab-
dominal aneurysm (AAA) repair [12] compared with
echocardiography derived measurements.
Given its straightforward setup and use, it seems that
the FloTrac/Vigileo is a useful tool correlating well with
the gold standard of the thermodilution method with
the PAC, in patients with a regular rhythm and stable re-
spiratory pattern and mechanics, hospitalized in an en-
vironment with less abrupt hemodynamic changes as is
the intensive therapy unit (ITU). While awaiting for
further studies to assess this relationship, a more cau-
tious approach should be adopted when it is used to as-
sess the CO in patients that rely on substantial
inotropic or vasopressor support or in environments
and settings with rapid dynamic changes, as in the op-
erating room (OR).Despite its relatively short presence in the market, the
non-invasive Nexfin monitor has also been validated
against the traditional methods of CO calculation, yield-
ing positive results so far. Two different research groups
demonstrated a reasonable correlation of CO values
obtained by the Nexfin when they were compared with
those calculated by transpulmonary thermodilution, both
in the setting of cardiac surgery [13,14]. The same good
agreement appears when the Nexfin derived CO values
are compared to those measured by Doppler echocardi-
ography, either from the transthoracic [15] or the
esophageal route [16]. Adding to these studies the lack
of invasiveness and the ease of use, the Nexfin monitor
appears to be an alternative method of calculating
hemodynamics where the traditional invasive approach
is difficult or undesirable.
Calibrated devices
The PiCCOplus monitor (Pulsion Medical Systems,
Munich, Germany), which is based on the pulse pressure
analysis to provide continuous real-time assessment of
the CO, uses the transpulmonary thermodilution for
intermittent calibration, being until recently the only de-
vice to incorporate this method in a commercial applica-
tion. This method is based on the same principle as the
traditional thermodilution but spares the need for a PAC
insertion. The technique starts with the injection of a
cold injectate in the superior vena cava (SVC) via a cen-
tral venous catheter (CVC) which mixes with the ambi-
ent blood and travels through the right heart, the
pulmonary vasculature and the left heart before reaching
the aorta. A thermistor in the aorta or a major arterial
branch measures the blood temperature and a
thermodilution curve of temperature over time, similar
to that from the PAC-based method but having a de-
layed peak temperature change, is plotted. The CO is
measured by the thermodilution equation:
CO ¼ TB−TIð Þ  K
∫∞0 ΔΤB tð Þdt
here TB=blood temperature, TI=injectate temperature,
and K=−computation constant (Figure 2).
The PiCCOplus monitor also provides information on
variables as the global end-diastolic volume (GEDV)
[17], which is an estimate of the preload much more re-
liable than the CVP, the intrathoracic blood volume
(ITBV), the extravascular lung water (EVLW), and
the pulmonary vascular permeability index (PVPI). The
combination of the last two variables could potentially
help in diagnosing pulmonary edema and distinguishing
between the hydrostatic and inflammatory forms of the
condition [18]. This comes at the cost of needing a CVC
for injection of the cold indicator and a thermistor-
Figure 2 The transpulmonary thermodilution curve, with the characteristic delay in the peak temperature change compared to the
PAC thermodilution. Based on the same principle as the PAC thermodilution, the transpulmonary method obviates the need for a PAC.
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brachial), this way being a more invasive method than
the FloTrac/Vigileo and the LidCO monitors.
Since a pulse contour method is used for continous CO
display, the same limitations as in the FloTrac/Vigileo
monitor apply for the PiCCOplus (IABP counterpulsation,
significant aortic regurgitation, arrhythmias). Sources of
potential errors that are specific for the transpulmonary
thermodilution come from the fact that the PiCCOplus
estimates the CO of the left heart whereas the PAC
thermodilution that of the right side. These should
be identical in ideal conditions, however a discrepancy
is encountered in the presence of intracardiac and
intrapulmonary shunts. Moreover, conditions related to
indicator loss in the tissues (that is, in the presence of pul-
monary edema) or recirculation will lead to a discrepancy
of the calculated CO compared to the one derived by the
PAC thermodilution, although these two phenomena may
actually cancel each other [19].
Regarding the reliability of the method, it appears that
there is good correlation of the CO measurements obtained
with the PiCCOplus compared to other methods. Two
studies performed on pediatric animal models by the
same scientific team showed a significant correlation
when the transpulmonary thermodilution derived values
were juxtaposed to those obtained with an ultrasound
probe around the main pulmonary artery, both in normal
cardiac anatomy and in the presence of a left-to-right
shunt [20,21].
An older study confirms the good performance of the
transpulmonary thermodilution even during substantialvariations in vascular tone and hemodynamics [22]. Tak-
ing these under consideration and calibrating the device
according to the manufacturer’s advice, it is reasonable
to consider the PiCCOplus as a reliable, less invasive
substitute method to the PAC.
The latest entry in the area of minimally invasive CO
monitoring using the transpulmonary thermodilution
comes from Edwards Lifesciences, which developed the
EV1000/VolumeView monitor (Edwards Lifesciences,
Irvine, CA, USA). Needing, as the PiCCOplus does, a spe-
cific to the set central arterial catheter and using a patented
for the company algorithm, it also displays volumetric pa-
rameters as the EVLW and GEDV but also a new variable
named the global ejection fraction (GEF). A recent clinical
validation study proved the interchangeability of this new
method to the PiCCOplus monitor, with VolumeView scor-
ing better in the calculation of GEDV [23].
The last of the calibrated CO monitors is the
LidCOplus (LidCO Ltd, Cambridge, UK) that utilizes the
lithium dilution technique. Based on the pulse power ra-
ther than the pulse pressure analysis via the PulseCO al-
gorithm, which does not rely on the arterial waveform
morphology, and needing only a peripheral arterial cath-
eter, the LidCOplus technology uses the lithium dilution
to intermittently calibrate the system. Specifically, bo-
luses of 0.5-2 mL of lithium chloride are each time
injected through a peripheral or central line and the lith-
ium concentration is measured through aspiration of
blood from the arterial catheter, using a Li+-sensitive
electrode attached to the catheter that generates a volt-
age [24]. Since the electrode has a low sensitivity for
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tor is applied for sodium plasma levels and a baseline
voltage is determined that helps differentiate the con-
centration of the two cations. Once the lithium dilu-
tion curve is obtained, the CO is calculated using the
Stewart-Hamilton equation, again with a correction for
packed cell volume. The main advantage of lithium as an
indicator is that it does not naturally occur in plasma and
therefore can generate a high signal-to-noise ratio when
used with a sensitive electrode, followed by a rapid
redistribution time and an insignificant first-pass loss
from the circulation [25].
Apart from the expected lack of accuracy of the
LidCOplus technology in a patient already on lithium
treatment, the other interference that should be taken
into account is the use of bolus doses of muscle relaxant
drugs in the operative and intensive care setting. High
peak doses of these drugs can cross-react with the lith-
ium sensor as they incorporate a positively charged qua-
ternary ammonia ion that can be detected by the sensor
and thus lead to an overestimation of the CO. Muscle
relaxant agents which are not compatible with the
LidCOplus monitor are atracurium and rocuronium,
whereas suxamethonium, vecuronium, and pancuronium
can be used provided that a time interval of 15–30 mi-
nutes elapses between their bolus administration and the
LidCOplus calibration.
The consistency of the CO measurement with the
LidCOplus technology compared to the traditionally
established thermodilution method with the PAC, has
been investigated in a number of validation studies. In
one of the most recent studies by Mora et al. [26], the
lithium dilution method showed good correlation and
marginal bias (0.28 L/min) with the thermodilution
method in patients with impaired left ventricular func-
tion after cardiac surgery. This good correlation was cor-
roborated by Costa et al. [27] when they validated the
LidCOplus against intermittent thermodilution measure-
ments in patients with hyperdynamic conditions. On the
other hand, the uncalibrated pulse power analysis using
the Pulse CO algorithm performed less well when used
in comparison to the PAC based thermodilution in pa-
tients undergoing CABG [28] or when used in very dy-
namic conditions such as the clamping and unclamping
of the aorta in AAA surgery [29]. Concluding, the
LidCOplus technology appears to be a reliable substitute
to the more invasive thermodilution method via the
PAC, provided that the system is calibrated in regular in-
tervals when an absolute value rather than a simple
trend of the CO is required.
Esophageal Doppler monitor
The Esophageal Doppler (ED) monitor, which is based
on the Doppler effect in order to measure the velocity ofblood flow, was first introduced in the 1970s as a non-
invasive means to measure CO. The velocity is calcu-
lated from the following equation:
V cfdð Þ= 2f0cosθð Þ
where v is the blood flow velocity, c is the speed of
sound in tissue, fd is the frequency shift, f0 is the fre-
quency of the emitted ultrasound, and θ is the angle be-
tween the ultrasound beam and the direction of the
blood flow. If the flow of blood in the descending aorta
is known, this figure can be used to estimate the stroke
volume and hence the cardiac output. The esophageal
Doppler measures the velocity of blood in the descend-
ing aorta in centimeters per second (cm/s). In order to
convert this figure into blood flow in milliliters per sec-
ond (mL/s), the diameter of the aorta needs to be
known. This is derived from published nomograms
based on age, sex, weight, and height (Deltex, West Sus-
sex, England) or through direct ultrasound measurement
(Arrow’s HemoSonic® Reading, PA, USA). The ED also
has the ability to measure the corrected flow time (FTc)
as a measure of cardiac preload. The FTc is the duration
of flow during systole corrected for a heart rate of 60
beats per minute. It is unclear as to whether the FTc or
SV should be used to guide fluid therapy, but it appears
that the ability to respond to a fluid challenge is best de-
termined by FTc. Several studies have compared FTc
with other indices such as pulmonary artery occlusion
pressure and have found good agreement between the
two [30-32].
There are some limitations to the usage of ED. First,
the ED only measures descending aortic blood flow,
which may not always be constant due aortic path-
ology or compression or due to abnormal upper to
lower body blood flow distribution. Also, the aortic
cross-sectional area is not constant, due to changes in
pulse pressure, vascular tone, aortic compliance, vol-
ume status, or catecholamine use. Due to the fact that
the radius of the aorta is squared in the final CO
equation, even small changes in aortic area can signifi-
cantly affect CO determinations [33]. Moreover, the
probe position is critical to obtain accurate measure-
ment for both blood flow measurement and aortic
cross-sectional measurement. The Doppler beam must
be within 20° of axial flow to obtain a good measure
of aortic blood flow. Even small misalignments of the
ultrasound beam with blood flow will lead to under-
estimation of flow when using the Doppler equation
[34,35]. Finally, the equation assumes that the flow is
laminar and any turbulent flow in the aorta will re-
duce measurement accuracy.
There have been studies that have compared ED mea-
surements of CO with PAC-derived thermodilution CO.
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the validity of ED monitoring as a measure of CO in
critically ill adults, concluding that the ED monitor has
high validity in tracking changes in CO [36]. In addition,
other studies have shown that using ED to guide fluid
administration improved patients’ management. Sinclair
et al. conducted a randomized controlled trial of patients
undergoing femoral fracture repair. Patients were ran-
domized to either routine care or ED-guided fluid
loading. The patients in the ED group had a shorter hos-
pital stay [37]. A similar trial conducted by Venn et al.
showed that the ED-monitored patients had less
intraoperative hypotension and were considered fit for
discharge earlier [38]. Noblett et al. [39] performed a
double-blind randomized control trial of Doppler-guided
fluid therapy versus anesthetist-directed fluid therapy in
108 patients undergoing elective colorectal resection.
They found that despite both groups of patients receiv-
ing the same volume of intraoperative fluids, the group
managed with the ED had a shorter hospital stay and
lower morbidity rates than the control group. Interest-
ingly, patients in the intervention group also had lower
levels of interleukin-6, which suggested an attenuated in-
flammatory response to surgery, perhaps due to the im-
proved organ perfusion. In a study by Wakeling et al.
patients recovered gut function significantly faster and
suffered significantly less gastrointestinal and overall
morbidity [40]. These overwhelming data in support of
the ED led the National Institute for Health and Clinical
Excellence (NICE) to release guidelines in 2011 advocat-
ing the use of this technology [41].
A completely non-invasive Doppler technology, the
USCOM (Ultrasound CO monitor, USCOM, Sydney,
Australia), is also available which uses Doppler technol-
ogy to measure CO from a suprasternal Doppler probe.
This technology has been studied in a few patient popu-
lation groups (mostly stable ICU patients) and has
shown reasonable correlation with PAC [42,43].
Thoracic electrical bioimpedance
Variations in the electrical impedance of the thorax to
an alternating current which occur synchronously with
the cardiac cycle were observed nearly 40 years ago. The
first use of this phenomenon to measure SV and CO
was described by Nyboer [44], and Kubicek and col-
leagues [45] introduced the technique into clinical prac-
tice in 1966.
Electrical bioimpedance involves the analysis of
intrabeat variations in transthoracic voltage in response
to the applied high frequency transthoracic current. Two
commercial devices based on electrical bioimpedance
use electrodes attached to an endotracheal tube (ECOM,
Conmed Corp, Utica, NY, USA) or the skin (BioZ, Cardio-
Dynamics, San Diego, CA, USA). Pulsatile changes inthoracic blood volume result in changes in electrical im-
pedance. The rate of change of impedance during systole
is measured and an estimate of the SV and the CO is de-
rived from a mathematical equation.
Sources of potential inaccuracies include motion arti-
facts, electrical interference, cardiac arrhythmias, heart
and lung pathologies (as chest deformities, pulmonary
edema, pleural and pericardial effusions, intracardiac
shunts), and foreign bodies (as chest tubes). Clinical tri-
als of TEB have been shown to be reliable in young
healthy volunteers, but in septic or surgical patients, the
results have been inconsistent [46-48].
Bioreactance
Recently, bioreactance (NICOM, Cheetah Medical Ltd,
Maidenhead, Berkshire, UK), a modification of thoracic
bioimpedance, has been introduced. Bioreactance refers
to the electrical resistance, capacitive and inductive
properties of blood and biological tissue that induce
phase shifts between an applied electrical current and
the resulting voltage signal. In contrast to bioimpedance,
the bioreactance technique analyzes the frequency spec-
tra variations of the delivered oscillating current. When
blood flows out of the heart, phase shifts occur if alter-
nating currents are applied across the patient’s chest.
Such phase shifts are conceptually similar to a frequency
modulation as used in radio transmission. The phase
shifts are measured continuously and have been shown
to relate almost linearly to blood flow in the aorta. This
results in less interfering from the electrical noise, pa-
tient movement, respiratory effort, lead placement, and
body mass index.
In addition to cardiac output, mean bioreactance mea-
surements are indicative of the total thoracic fluid con-
tent (TFC). TFC is affected by both intravascular and
extravascular fluid in the chest cavity and although it
does not correlate with pulmonary artery wedge pressure
(PAWP), its changes are very reliable indicators of
the changes in intravascular or extravascular fluid vol-
ume [49]. In a study of patients undergoing cardiac sur-
gery, the bioreactance did well initially in determining
CO when compared with PAC, however, during the im-
mediate postoperative period, the correlation was not as
robust [50].
It appears that the new generation of devices might be
better than the first generation TEB machines, although
there are still limitations regarding their accuracy in
measuring CO during dynamic conditions.
Gas rebreathing
The partial carbon dioxide (CO2) rebreathing technique
uses the Fick principle applied to the CO2 in order to esti-
mate CO non-invasively. The NICO monitor (Novametrix
Medical Systems, Inc., Wallingford, CT, USA) imple-
Figure 3 Correlation of fluid responsiveness with SVV/PPV
variables. As a general rule, the higher the SVV/PPV values, the
more fluid responsive the patient will be. The correlation can only
be applied to mechanically ventilated patients.
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disposable rebreathing loop. The monitor consists of a
CO2 sensor, a disposable airflow sensor and a pulse oxim-
eter. CO2 production (VCO2) is calculated from minute
ventilation and its CO2 content, whereas the arterial CO2
content (CacO2) is estimated from end-tidal CO2, with
adjustments for the slope of the CO2 dissociation curve
and the degree of dead space ventilation. The partial re-
breathing reduces CO2 elimination and increases end-
tidal CO2. Measurements under normal and rebreathing
conditions allow one to omit the venous CO2 content
(CvCO2) measurement in the Fick equation, because
CvCO2 does not change during this brief period of re-
breathing [51].
CO¼VCO2= CvCO2‐CaCO2ð Þ
While the technique is easy to use, the correlation be-
tween the NICO and standard thermodilution has been
shown to be adversely affected in spontaneously breath-
ing patients, which limits the number of suitable candi-
dates [52,53]. Partial rebreathing has been shown to
be more accurate in less critically ill patients with nor-
mal alveolar gas exchange when compared with PAC
thermodilution [54,55]. Severe chest trauma, significant
intrapulmonary shuntdead-space ventilation, low mi-
nute ventilation, and high CO may all reduce accuracy
[56]. There have been no reports on the device when
used in hemodynamically unstable patients [57]. More-
over, the partial-rebreathing technique only measures
the CO and does not provide information on the intra-
vascular volume status or fluid responsiveness. For
these reasons, partial gas rebreathing is limited in its
clinical applicability.
Transesophageal echocardiography
Widely used in the cardiac operative and postoperative
setting to demonstrate cardiac anatomy and identify
pathology, the transesophageal echocardiography (TOE)
has been impractical in assisting with continuous CO
measurements outside the operative theater because of
the size of the probe and the limitations that come with
it. However, the recent development of a miniaturized
5 mm TOE probe (ClariTEE Probe, ImaCor Inc., Garden
City, NY, USA) that can stay indwelled for up to 72
hours, has enabled hemodynamic management of the
critically ill patients [58]. Although not a CO monitoring
per se, the ClariTEE uses a monoplane transducer
that enables the operator to acquire basic views of the
heart (ascending aortic short-axis, four-chamber, and
transgastric short-axis) that, combined with a software
tool, offer continuous calculations of the ventricular
size and systolic performance. Moreover, echocardiographyderived measurements of the stroke volume can help in the
assessment of fluid responsiveness [59]. Validation studies
are pending.
Predicting fluid responsiveness
The assessment of intravascular volume status of an in-
dividual has been traditionally performed with static pa-
rameters, mainly filling pressures such as CVP and
PAWP, which reflect the preload of the right and the left
ventricles, respectively. It is now acknowledged that
these values correlate poorly with the intravascular vol-
ume and the response to a fluid bolus [60], hence there
has been a shift to more dynamic indices such as the
stroke volume variation (SVV) and the pulse pressure
variation (PPV).
All the devices that use the pulse pressure analysis
method for CO monitoring, also calculate those two pa-
rameters. Based on the effect of the cyclic variation of
intrathoracic pressures with respiration on the preload
of the left ventricle and using appropriate algorithms,
the beat to beat variation of the SV and the pulse pres-
sure (PP) is calculated. Specifically, positive pressure
ventilation induces cyclic changes in vena cava blood
flow, pulmonary artery flow, and aortic blood flow.
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ous return decreases) and, according to the Frank-
Starling relationship, pulmonary artery flow decreases.
Approximately three beats later this decrease in pulmon-
ary artery flow is transmitted to the left ventricle indu-
cing a decrease in SV and aortic PP. As a general rule,
values of SVV >10% and PPV >13% are indicative of pa-
tients that will probably respond to the administration
of fluids, while lower values indicate the opposite. The
basic limitation is that the above calculations can only
be applied to mechanically ventilated patients, as the
correlation in spontaneously breathing individuals is
weaker. Moreover, for optimal results the tidal volume
(TV) should be >8 mL/Kg of body weight, the patient
should be in sinus rhythm, and the chest must be closed
[61] (Figure 3).
More recently, a new index called the Pleth Variability
Index (PVI) may help with the prediction of fluid re-
sponsiveness. The PVI is continuously calculated by the
new non-invasive Masimo monitor (Masimo Corpor-
ation, Irvine, CA, USA), a device that resembles the
traditional pulse oximeter. The monitor measures first
the change during a respiratory cycle of the Perfusion
Index (PI), which is the ratio of non-pulsatile to pulsatileTable 1 Overview and classification of minimally invasive CO
Modality Available devices
Pulse pressure analysis
-Uncalibrated devices Flo/Trac-Vigileo
Pulsioflex
LidCO rapid
-Calibrated devices LidCO plus
PiCCOplus
Volumeview
Doppler
-Transesophageal CardioQ/CardioQ-OCM
-Transthoracic USCOM
Echocardiography ClariTEE
Gas rebreathing NICO
Bioimpedance/ Bioreactance
-Thoracic electrical bioimpedance
- Bioreactance BioZ
NICOM
Non-invasive monitors
Nexfin
Masimo
esCCOblood flow through the peripheral capillary bed, and
then calculates the PVI from the following formula:
PVI¼ PImax‐PIminð Þ=PImax½ x100
The greater the PVI value is, the more likely the pa-
tient will respond to fluid administration [62]. As is the
case with SVV and PVV, one should always bear in mind
the same limitations before taking clinical decisions re-
garding the hemodynamic optimization of patients
(Table 1).
Goal-directed therapy
All the above methods of quantifying the CO have the
potential to reduce the morbidity and mortality of the
patients if they are integrated into appropriate protocols
that guide the therapeutic interventions. The use of CO
measurements to guide fluid administration and ino-
tropic therapy, optimizing this way the tissue perfusion
and cellular oxygenation has been given the broad term
goal-directed therapy (GDT). Its beneficial effects dem-
onstrated as early as the late 1970s by the seminal work
of Shoemaker and his team [63,64], it is now acceptedmonitors
Requirements Additional values
Standard arterial line GEDV, EVLW
Standard arterial line
Standard arterial line
Standard arterial line
Standard arterial line
Central venous line
Standard arterial line
Central venous line GEDV, EVLW, GEF
Transesophageal probe FTc
Transthoracic probe
Miniaturized transesophageal probe
Disposable rebreathing circuit
Specific electrodes
Specific electrodes
Finger probe Hb
Specific pulse oximeter PVI
ECG/ specific pulse oximeter PWTT
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rates in both surgical [2,65,66] and non-surgical popula-
tions [67]. With increasing availability of a variety of
minimally invasive CO monitors, one should expect the
GDT to be widely implemented for the hemodynamic
optimization of various patients’ groups, especially when
questions regarding the cost-effectiveness of the method
are adequately addressed.
Conclusions
A whole array of minimally invasive devices and monitors
that can reliably calculate trends in the CO without the
need for a PAC are now available to the clinicians. Need-
ing only peripheral or central arterial catheters or only a
finger probe, as is the case in the Nexfin and Masimo
monitors, they can give reliable measurements of CO and
of dynamic indices such as the SVV and the PPV, provided
that their limitations are taken into account.
Additional tools in the area of minimal invasiveness
are the OD, with its use strongly advocated by recent
NICE guidelines, and the less widely used gas rebreath-
ing and thoracic bioimpedance methods. Last, the intro-
duction of a miniaturized TOE probe may revolutionize
the management of ITU patients, providing real-time in-
formation on cardiac anatomy and function.
The integration of these devices into therapeutic pro-
tocols enables the clinician to apply GDT and guide the
inotropic support and fluid administration in a rational
way, reducing this way the mortality and morbidity of
the patients.
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